Lv31
220 积分 2024-11-18 加入
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D
7小时前
已完结
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D
7小时前
已完结
Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)
7小时前
已完结
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
7小时前
已完结
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer – Outcome and novel predictive markers
7小时前
已完结
Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
8小时前
已完结
The colorectal cancer drug market
8小时前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
8小时前
已完结
Immunotherapy Efficacy in Mismatch Repair–Proficient Colorectal Cancer Patients With and Without Liver Metastases
8小时前
求助中
Updated Survival Outcome of Regorafenib, Ipilimumab, and Nivolumab in Refractory Microsatellite Stable Non-Liver Metastatic Colorectal Cancer: A Phase I Nonrandomized Clinical Trial
8小时前
已完结
皖公网安备34019202002308
